Sunday 18 October 2026
Export TNXP’s income statement to Excel — free account
Tonix Pharmaceuticals Holding Corp.
TNXP Healthcare Biotechnology
Tonix Pharmaceuticals Holding Corp.’s revenue for fiscal 2025 (year ended December 2025) was $13.1 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 577.9%, EPS grew 36.8% and free cash flow fell 178.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.04
0.38
−5.92%
Follow TNXP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Piotroski F-Score |
5 | — | — | — | — | — | — | — | — | — |
Altman Z-Score |
(2.42) | (7.62) | (7.57) | — | — | — | — | — | — | — |
P/S ratio |
10.14 | 2.41 | 0.00 | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(0.37) | (9.93) | (14.34) | — | — | — | — | — | — | — |
Beneish M-Score |
(2.38) | — | — | — | — | — | — | — | — | — |
P/Operating CF |
(3.35) | (1.66) | (0.48) | — | — | — | — | — | — | — |
P/B ratio |
0.54 | 0.17 | 0.10 | — | — | — | — | — | — | — |
Price to Tangible BV |
0.54 | 0.17 | 0.11 | — | — | — | — | — | — | — |
EV/Sales |
(5.13) | (6.64) | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
0.54 | 0.51 | 0.05 | — | — | — | — | — | — | — |
EV/Operating CF |
0.67 | 1.10 | 0.05 | — | — | — | — | — | — | — |
EV/FCF |
0.65 | 1.10 | 0.05 | — | — | — | — | — | — | — |
Quick Ratio |
6.94 | 5.60 | 1.32 | 7.06 | 8.58 | 8.63 | 2.19 | 9.43 | 11.99 | 12.34 |
Current Ratio |
7.42 | 6.50 | 2.53 | 7.19 | 8.71 | 8.96 | 2.72 | 9.81 | 12.44 | 12.83 |
Net Debt/EBITDA |
1.68 | 0.69 | 0.14 | 1.08 | 1.93 | 1.50 | 0.38 | 0.95 | 1.20 | 0.67 |
Debt/Assets |
0.00% | 4.60% | 5.77% | 0.34% | 0.40% | 1.34% | 2.46% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.05 | 0.08 | 0.00 | 0.00 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.81 | 0.47 | 0.87 | 0.84 | 0.82 | 0.93 | 0.86 | 0.82 | 0.91 | 0.96 |
Capex/Depreciation |
(1.69) | (0.03) | (1.61) | (38.43) | (706.14) | (317.19) | (0.65) | (0.11) | (0.07) | (0.32) |
Interest Coverage |
(1,412.39) | (110.78) | — | (59.85) | (3,692.48) | — | — | 112.97 | 126.73 | 306.84 |
| (64.48%) | (106.12%) | (74.61%) | (54.88%) | (60.25%) | (107.50%) | (187.97%) | (121.60%) | (84.53%) | (118.38%) | |
| (56.37%) | (81.95%) | (61.38%) | (50.10%) | (54.43%) | (92.56%) | (152.12%) | (110.62%) | (77.85%) | (104.23%) | |
ROIC |
(209.43%) | (177.00%) | (82.68%) | (79.87%) | (140.67%) | (265.49%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(51.14%) | (90.97%) | (94.91%) | (56.62%) | (42.35%) | (60.15%) | (351.44%) | (125.21%) | (86.54%) | (154.29%) |
Average Days of Receivables |
174.63 | 133.18 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
339.41% | 396.00% | 1,115.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
668.99% | 397.28% | 447.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
45.91% | 47.34% | 119.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
1.48 | 3.94 | (0.11) | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(93.32%) | (7,684.39%) | (1,630.69%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(77.63%) | (251.24%) | (1,025.65%) | — | — | — | — | — | — | — |
Revenue per Share |
1.54 | 13.71 | 983.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(11.73) | (82.74) | (12,911.77) | (54,473.89) | (125,928.33) | (0.51) | (16.58) | (212.13) | (28.68) | (14.80) |
Capex per Share |
(0.40) | (0.16) | (872.91) | (26,748.33) | (58,845.00) | (0.09) | (0.01) | (0.05) | (0.01) | (0.03) |
Free Cash Flow per Share |
(12.13) | (82.91) | (13,784.68) | (81,222.22) | (184,773.33) | (0.60) | (16.59) | (212.19) | (28.69) | (14.83) |
Cash per Share |
24.40 | 134.15 | 3,157.97 | 66,793.89 | 297,766.67 | 0.81 | 6.99 | 221.54 | 38.22 | 10.36 |
Shareholders Equity per Share |
28.80 | 189.54 | 13,357.59 | 115,101.11 | 364,528.33 | 0.93 | 5.85 | 209.42 | 36.91 | 10.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
28.80 | 189.54 | 13,357.59 | 115,101.11 | 364,528.33 | 0.93 | 5.85 | 209.42 | 36.91 | 10.06 |
Free Cash Flow |
(103.21) | (61.04) | (108.90) | (146.20) | (110.86) | (57.13) | (26.70) | (23.98) | (19.13) | (37.38) |
Working Capital |
198.04 | 100.70 | 28.88 | 112.60 | 167.33 | 78.17 | 8.81 | 23.40 | 24.32 | 25.02 |
Capital Expenditures |
(3.37) | (0.12) | (6.90) | (48.15) | (35.31) | (8.56) | (0.02) | (0.01) | 0.00 | (0.07) |
Net Current Asset Value |
196.86 | 95.67 | (1.16) | 112.27 | 166.87 | 77.45 | 8.81 | 23.40 | 24.31 | 24.99 |
EV/EBIT |
0.53 | 0.49 | 0.05 | — | — | — | — | — | — | — |
Capex to Sales |
0.26 | 0.01 | 0.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.04 | 0.10 | 0.05 | 0.01 | 0.00 | 0.00 | 0.76 | 1.26 | 0.77 | 1.37 |
Cash ROIC |
(22.80%) | (24.83%) | (78.13%) | (44.55%) | (27.83%) | (34.41%) | (127.00%) | (49.24%) | (38.18%) | (72.61%) |
Accounts Receivable Turnover |
2.63 | 1.72 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
1.05 | 1.86 | 0.80 | 0.12 | 0.01 | 0.01 | 0.01 | 0.04 | 0.06 | 0.11 |
Inventory Turnover |
0.92 | 0.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
446.03 | 213.69 | 291.17 | 2,350.22 | 96,958.60 | 62,158.15 | 43,098.08 | 9,490.00 | 7,391.25 | 1,545.05 |
Days of Inventory on Hand |
330.53 | 395.22 | 1,050.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
4.98 | 5.86 | — | 7.88 | 7.68 | 7.68 | — | — | — | — |
Average Payables |
6.33 | 4.16 | 5.93 | 10.68 | 8.94 | 3.83 | 2.24 | 1.35 | 1.08 | 1.96 |
Average Inventory |
7.21 | 11.02 | — | — | — | — | — | — | — | — |
Average Assets |
220.03 | 158.67 | 190.07 | 233.30 | 169.54 | 56.37 | 20.44 | 26.54 | 27.13 | 37.26 |
Average Common Equity |
192.35 | 122.54 | 156.35 | 212.95 | 153.18 | 48.53 | 16.54 | 24.14 | 24.99 | 32.81 |
Columns are period end dates